Elite Health Systems Inc. has announced that its subsidiary, Elite Health Plan, Inc., has received conditional approval from the Centers for Medicare and Medicaid Services $(CMS)$ for its Contract Year 2026 Medicare Advantage/Medicare - Prescription Drug (MA-Only/MA-PD) application. This marks a significant step for Elite Health Plan, allowing them to advance in the CMS regulatory process. However, final approval is contingent upon CMS's acceptance of Elite Health Plan's bid and formulary, as well as the completion of necessary pre-implementation activities, including system and data testing. The bid submission was conducted in partnership with Wakely Consulting Group. The process remains complex, and there is no assurance of ultimate approval or license maintenance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。